Effects of 1-year Tofacitinib Therapy on Angiogenic Biomarkers in Rheumatoid Arthritis

This study by Kerekes, et al. investigated the relationship between tofacitinib therapy, angiogenic biomarker levels, and vascular inflammation and function in RA patients. The authors found that tofacitinib treatment reduced the production of bFGF, PlGF and IL-6, which may inhibit synovial and aortic inflammation.

Biomarkers were assessed at baseline and at 6 and 12 months after initiating tofacitinib therapy. RA patients had DAS28 >3.2 at baseline and a clinical indication for targeted therapy.